Subscribe!
CURE

A NEWSLETTER FROM CURE MAGAZINE / CURETODAY.COM



Photo Courtesy (c) ASCO/Todd Buchanan 2012

‘Super Herceptin’ Excels in HER2 Breast Cancer
At the American Society of Clinical Oncology's annual meeting, investigational breast cancer drug T-DM1 became the headliner when researchers announced the drug slows down disease progression and may extend survival. The drug had a sputtering start when the Food and Drug Administration refused to grant it accelerated approval in 2010, even with promising phase 2 data. The latest clinical trial, a phase 3 study called EMILIA, may have what it takes to get a nod from the FDA... READ MORE >


Afatinib Helps Delay Lung Cancer Progression
Results from a phase 3 trial showed the targeted drug afatinib significantly improves progression-free survival among patients with advanced lung cancer that harbors certain genetic mutations compared with standard chemotherapy... READ MORE >

Antidepressant Works in Treating Neuropathy
Patients who experience chemotherapy-induced peripheral neuropathy, an often painful side effect, may find relief with the antidepressant Cymbalta (duloxetine), according to results from a phase 3 study... READ MORE >

New Drug Regimen Edges Out Standard Chemotherapy in Lymphomas
Combining Treanda (bendamustine) and Rituxan (rituximab) more than doubles progression-free survival time in patients with slow-growing and mantle cell lymphomas compared with standard chemotherapy... READ MORE >

New Targeted Therapies for Advanced Melanoma Patients
Two new targeted therapies, which each focus on a different way to block cancer growth signaling, delayed disease progression in patients with advanced, BRAF-mutated melanoma, according to results from separate phase 3 trials... READ MORE >

Avastin Produces Results in Chemo-Resistant Ovarian Cancer
Although most cases of ovarian cancer respond to paclitaxel or other platinum-based chemotherapies, about 20 percent of cancers continue to progress with initial treatment while other cases later become resistant. To tackle these platinum-resistant cancers, a French research group examined adding Avastin (bevacizumab) to standard chemotherapy... READ MORE >

Continuous Hormone Therapy Better for Men With Advanced Prostate Cancer
In an international phase 3 trial, men with metastatic prostate cancer lived longer with continuous hormone therapy compared with intermittent therapy (5.8 years compared with 5.1 years). However, men with minimal metastases had an even greater benefit—nearly a two-year survival advantage... READ MORE >

Genetic Marker Identifies Brain Cancer Patients Who Benefit from Chemo-Radiation Combination
Patients with anaplastic oligodendroglial tumors harboring certain chromosomal deletions had a 44 percent reduced risk of dying after receiving radiation followed by chemotherapy versus radiation alone... READ MORE >

Blog: HPV Status in Head and Neck Cancer May Affect Treatment Decisions
For the Summer feature, we're highlighting head and neck cancer that is associated with HPV, the human papillomavirus. Although this virus first gained public awareness as a cause of cervical cancer, it's increasingly linked to other cancers, such as vaginal, penile and anal. Recently, however, it was discovered that most head and neck cancers are linked to HPV... READ MORE >

Blog: ASCO Wrap-Up
One advantage to attending the annual meeting of the American Society of Clinical Oncology is being able to ascertain the "buzz" among oncologists. What developments excite them? What will findings will they implement upon returning to their practices? ... READ MORE >


ADVERTISEMENT


ADVERTISEMENT


ADVERTISEMENT


Combining science with humanity, CURE makes cancer understandable.



Send feedback to editor@curetoday.com

This email was sent to you because you have provided your email address to CURE. CURE is committed to protecting your privacy and no information about our subscribers is sold to any outside party.

© 2012 CURE Media Group. All rights reserved.

Disclaimer: CURE does not provide medical, diagnostic or treatment advice. Terms of Use